RxDoctor Payments Data

Louis Agnone, MD

Gastroenterology · Port Orange, FLNPI 1699775619

Payments from drug & device makers

$14,171in general payments, 2019–2025

Across 727 payments — averaging $19.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Johnson & Johnson$2K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
  • QOL Medical, LLC$1K
  • Takeda Pharmaceuticals U.S.A., Inc.$1K
  • Merck$705
  • plus $5K from 37 others

What the payments were for

  • Food & beverage$14,06999%
  • Education$1021%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,171 in reported general payments places this provider in the 75th percentile of 1,388 gastroenterology providers in Florida.

See all gastroenterology providers in Florida

Medicare billing

Part B allowed, 2024
$187,825
Medicare patients
700
Services billed
1,301

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide31$20,628
ClenpiqSod Picosulf/Mag Ox/Citric Ac97$16,542
Mesalamine28$15,745
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates205$12,530
MovantikNaloxegol Oxalate15$6,704
Mesalamine ErMesalamine12$3,234
Balsalazide Disodium12$2,294
Sucralfate31$2,013
Omeprazole155$1,954
SutabSod Sulf/Pot Chloride/Mag Sulf11$1,781
Famotidine90$1,445
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl72$1,220
Esomeprazole Magnesium29$1,103
Pantoprazole Sodium73$781
Bethanechol Chloride13$769

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$2,644$20,62831 claims
Ferring Pharmaceuticals Inc.Clenpiq$13$16,54297 claims
Redhill Biopharma Inc.Movantik$267$6,70415 claims
Braintree Laboratories, Inc.Sutab$50$1,78111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,388 gastroenterology providers in Florida.

Other gastroenterology in Port Orange

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →